Market Overview:
The global glatiramer acetate market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of multiple sclerosis (MS) and rising demand for better treatment options. Glatiramer acetate is a drug used in the treatment of MS, and it is available as both a brand medicine and a generic drug. The brand medicines are more expensive than the generic drugs, but they are more popular due to their higher efficacy. However, with the increasing competition among generics manufacturers, the prices of generic drugs are expected to decline in the coming years. The hospital segment dominates this market owing to its high usage rates for treating MS patients. However, with growing awareness about glatiramer acetate and its benefits among patients and healthcare professionals alike, other application segments such as pharmacies and other are also expected to witness significant growth during the forecast period.
Product Definition:
Glatiramer acetate (trade name Copaxone) is a drug used to treat multiple sclerosis. It is a synthetic peptide composed of four amino acids: alanine, glutamic acid, tyrosine, and lysine. These are the same amino acids found in myelin basic protein, a component of the myelin sheath that surrounds nerve fibers in the central nervous system. Glatiramer acetate is believed to work by mimicking this protein and interfering with the autoimmune response that damages myelin.
Brand Medicine:
The global brand medicine market is expected to grow at a lucrative rate during the forecast period. Brand medicines are those products which have been recognized by the government as an essential medication and whose consumption cannot be postponed in any category of illness. The demand for these drugs is constantly increasing due to their efficiency in treating chronic disorders, such as rheumatoid arthritis, osteoarthritis, asthma, etc., and acute diseases like influenza or malaria.
Generic Drug:
A generic drug is a pharmaceutical product that has an active ingredient similar to that of a branded drug but which is not the exact same as the patented medicine. The generic version of the product usually costs less than the original, and in many cases, it may even be cheaper. There are various types of generic drugs available in the market varying from low-cost to high-priced depending on their brands.
Application Insights:
Glatiramer acetate is used for the treatment of multiple sclerosis in patients who have not responded to other therapies. The drug is approved by the U.S. FDA and Health Canada for this use, under brand name Copaxone and Stemfrut, respectively. Other applications of glatiramer acetate include cerebral palsy, post-stroke rehabilitation therapy, spinal cord injuries and others.
Regional Analysis:
North America was the largest regional market in 2017 owing to the presence of a large number of patients suffering from multiple sclerosis and high healthcare expenditure. The U.S. accounted for more than 80% share in North America region due to higher adoption of brand drugs, better reimbursement scenario, and availability of advanced treatment options for patients with multiple sclerosis at affordable prices. In addition, increasing prevalence rate is also expected to drive growth over the forecast period.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global Glatiramer Acetate market is expected to grow at a CAGR of XX% during the forecast period owing to the increasing incidence of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and Crohn’s disease.
- Rising awareness about Glatiramer Acetate: There is a growing awareness among people about the benefits of Glatiramer Acetate therapy which is propelling the growth of this market.
- Technological advancements in drug delivery systems: The development and commercialization of novel drug delivery systems for Glatiramer Acetate are providing impetus to the growth of this market. These systems help in improving patient compliance and efficacy while reducing side effects associated with traditional injections.
- Growing demand for long-term therapies: There is an increasing demand for long-term therapies due to their better safety and efficacy profiles as compared to short-term treatments options available in the market currently. This is driving the growth of the global Glatiramer Acetate market significantly over the forecast period 2017 – 2025..
Scope Of The Report
Report Attributes
Report Details
Report Title
Glatiramer Acetate Market Research Report
By Type
Brand Medicine, Generic Drug
By Application
Hospital, Pharmacy, Other
By Companies
Teva, NATCO Pharma, Mylan, Novartis, HYBIO
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Glatiramer Acetate Market Report Segments:
The global Glatiramer Acetate market is segmented on the basis of:
Types
Brand Medicine, Generic Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- NATCO Pharma
- Mylan
- Novartis
- HYBIO
Highlights of The Glatiramer Acetate Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Brand Medicine
- Generic Drug
- By Application:
- Hospital
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glatiramer Acetate Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glatiramer Acetate is a medication used to treat multiple sclerosis (MS). It is an injectable medicine that helps reduce the number of attacks in people with MS. Glatiramer Acetate may also help improve disability and quality of life.
Some of the major players in the glatiramer acetate market are Teva, NATCO Pharma, Mylan, Novartis, HYBIO.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Glatiramer Acetate Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Glatiramer Acetate Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Glatiramer Acetate Market - Supply Chain
4.5. Global Glatiramer Acetate Market Forecast
4.5.1. Glatiramer Acetate Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Glatiramer Acetate Market Size (000 Units) and Y-o-Y Growth
4.5.3. Glatiramer Acetate Market Absolute $ Opportunity
5. Global Glatiramer Acetate Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Glatiramer Acetate Market Size and Volume Forecast by Type
5.3.1. Brand Medicine
5.3.2. Generic Drug
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Glatiramer Acetate Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Glatiramer Acetate Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Pharmacy
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Glatiramer Acetate Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Glatiramer Acetate Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Glatiramer Acetate Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Glatiramer Acetate Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Glatiramer Acetate Demand Share Forecast, 2019-2026
9. North America Glatiramer Acetate Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Glatiramer Acetate Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Glatiramer Acetate Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Pharmacy
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Glatiramer Acetate Market Size and Volume Forecast by Type
9.7.1. Brand Medicine
9.7.2. Generic Drug
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Glatiramer Acetate Demand Share Forecast, 2019-2026
10. Latin America Glatiramer Acetate Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Glatiramer Acetate Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Glatiramer Acetate Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Pharmacy
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Glatiramer Acetate Market Size and Volume Forecast by Type
10.7.1. Brand Medicine
10.7.2. Generic Drug
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Glatiramer Acetate Demand Share Forecast, 2019-2026
11. Europe Glatiramer Acetate Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Glatiramer Acetate Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Glatiramer Acetate Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Pharmacy
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Glatiramer Acetate Market Size and Volume Forecast by Type
11.7.1. Brand Medicine
11.7.2. Generic Drug
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Glatiramer Acetate Demand Share, 2019-2026
12. Asia Pacific Glatiramer Acetate Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Glatiramer Acetate Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Glatiramer Acetate Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Pharmacy
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Glatiramer Acetate Market Size and Volume Forecast by Type
12.7.1. Brand Medicine
12.7.2. Generic Drug
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Glatiramer Acetate Demand Share, 2019-2026
13. Middle East & Africa Glatiramer Acetate Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Glatiramer Acetate Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Glatiramer Acetate Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Pharmacy
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Glatiramer Acetate Market Size and Volume Forecast by Type
13.7.1. Brand Medicine
13.7.2. Generic Drug
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Glatiramer Acetate Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Glatiramer Acetate Market: Market Share Analysis
14.2. Glatiramer Acetate Distributors and Customers
14.3. Glatiramer Acetate Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teva
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. NATCO Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mylan
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. HYBIO
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook